Key result
Higher p-cresyl sulfate levels linked to ~10% higher odds of arterial stiffness in CKD.
Why the study?
Although PCS causes cardiovascular injury in CKD and baPWV predicts cardiovascular events, the correlation between serum PCS levels and peripheral arterial stiffness in stage 3 to 5 CKD was not established.
Does elevated serum p-cresyl sulfate level increase the risk of peripheral arterial stiffness in patients with non-dialysis stage 3-5 chronic kidney disease?
Cross-Sectional (n=160)
No
Does elevated serum p-cresyl sulfate level increase the risk of peripheral arterial stiffness in patients with non-dialysis stage 3-5 chronic kidney disease?
Serum p-cresyl sulfate acts as a potential independent predictor of peripheral arterial stiffness in patients with moderate-to-advanced chronic kidney disease, highlighting the cardiovascular role of uremic toxins.
Answers are grounded in this paper and cite their sources.
May support p-cresyl sulfate as vascular risk marker in CKD; hypothesis-generating, does not yet inform practice.
p-Cresyl sulfate (PCS) is a uremic toxin that causes cardiovascular injury and progression in patients with chronic kidney disease (CKD). Peripheral arterial stiffness (PAS) as measured using the brachial-ankle pulse wave velocity (baPWV) is considered a valuable predictor of cardiovascular event risk in the general population. The study investigated the correlation between serum PCS levels and PAS (baPWV > 18.0 m/s) in 160 patients with stage 3−5 CKD. Liquid chromatography−mass spectrometry was used to assay serum PCS levels. PAS was detected in 54 patients (33.8%), and it was linked to older age, a higher prevalence of hypertension, higher systolic and diastolic blood pressure, higher serum calcium−phosphorus product and PCS levels, and lower height and body weight. Multivariable logistic regression analysis for independent factors associated with PAS illustrated that, in addition to age and diastolic blood pressure, serum PCS levels exhibited an odds ratio (OR) of 1.098 (95% confidence interval = 1.029−1.171, p = 0.005). These findings demonstrated that serum PCS levels were associated with PAS among patients with stage 3−5 CKD.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2022) conducted a cross-sectional in Non-Dialysis Chronic Kidney Disease Stage 3 to 5 (n=160). Serum p-cresyl sulfate level was evaluated on Peripheral arterial stiffness (baPWV > 18.0 m/s) (OR 1.098, 95% CI 1.029-1.171, p=0.005). Higher serum p-cresyl sulfate levels were independently associated with the presence of peripheral arterial stiffness in patients with stage 3-5 chronic kidney disease (OR 1.098).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: